Qi Yan-Xiu, Liu Hong-Wei, Sun Quan, Su Xing-Jie, Han Lin
Department of Ophthalmology, First Affiliated Hospital of Jiamusi University.
Department of Biology Laboratory, Jiamusi University School of Basic Medicine.
Medicine (Baltimore). 2020 Nov 20;99(47):e23245. doi: 10.1097/MD.0000000000023245.
Primary open-angle glaucoma (POAG) is a very common disorder, and it is the second leading cause that results in blindness worldwide after cataracts. Previous studies have reported that dorzolamide/timolol-fixed combination (DTFC) can be used in treating POAG. However, there are still inconsistent results. Thus, this study will systematically investigate the efficacy and safety of DTFC on POAG.
A comprehensive search will be carried out in Cochrane Library, MEDLINE, EMBASE, CINAHI, ACMD, China National Knowledge Infrastructure, and WANGFANG database from origin to the present. There are no limitations related to the language and publication status. Only randomized controlled trials that assessed the efficacy and safety of DTFC for the treatment of POAG will be included. Two researchers will independently undertake record selection, data extraction, and study quality assessment. Any divisions will be solved by discussion with a third researcher. We will perform statistical analysis using RevMan 5.3 software RESULTS:: This study will summarize the present evidence to identify the efficacy and safety of DTFC in treating POAG through mean intraocular pressure, best corrected visual acuity, contrast sensitivity, bioelectric activity of the retina, rate of progression of glaucoma, quality of life, and adverse events.
The results of this study will provide evidence of DTFC for the treatment of POAG.
INPLASY202040120.
原发性开角型青光眼（POAG）是一种非常常见的疾病，是全球仅次于白内障导致失明的第二大主要原因。既往研究报道，多佐胺/噻吗洛尔固定复方制剂（DTFC）可用于治疗POAG。然而，结果仍不一致。因此，本研究将系统地调查DTFC治疗POAG的有效性和安全性。
将对Cochrane图书馆、MEDLINE、EMBASE、CINAHL、ACMD、中国知网和万方数据库进行全面检索，检索时间从建库至目前。不设语言和发表状态限制。仅纳入评估DTFC治疗POAG有效性和安全性的随机对照试验。两名研究人员将独立进行记录筛选、数据提取和研究质量评估。任何分歧将通过与第三名研究人员讨论解决。我们将使用RevMan 5.3软件进行统计分析。结果：本研究将通过平均眼压、最佳矫正视力、对比敏感度、视网膜生物电活动、青光眼进展率、生活质量和不良事件等方面总结现有证据，以确定DTFC治疗POAG的有效性和安全性。
本研究结果将为DTFC治疗POAG提供证据。
INPLASY202040120。
